Spotlight -

B + L Dry Eye Series|

Transforming Glaucoma Management|

Zeiss Clinical Cases

Viewing

|Articles|December 15, 2001

Why Your Practice Should Consider Pediatric Dispensing

Are you considering adding pediatric optical dispensing to your practice?

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Content

Frantz EyeCare LAL outcomes exceed national benchmarks in single-center cataract data

ByLucia Gambuzza

July 30th 2026

QandA with Ping Moore, OD

Emerging dry eye therapies and co-managing MGD: Ping Moore, OD

ByYun Ping Moore, OD,Lucia Gambuzza

Published: July 23rd 2026 | Updated: July 23rd 2026

(Image courtesy of Peter J. McDonnell, MD) Why aren’t there enough ophthalmologists?

Why aren’t there enough ophthalmologists?

ByPeter J. McDonnell, MD

July 20th 2026

Personalizing dry eye treatment by addressing disease at its source

ByMarjan Farid, MD

July 17th 2026

Q&A with Esen Akpek, MD | Ophthalmology Times

Root cause–based dry eye classification and the shift toward precision medicine

ByLucia Gambuzza,Esen K. Akpek, MD

July 15th 2026

Latest CME

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

Uday Devgan, MD, FACS, FRCS

(CME) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

(CME) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

Damon Dierker, OD FAAO; Maria Pribis, OD

Trending on Eye Care Network - Ophthalmology Times

Retina Society 2026: MCO-010 optogenetic therapy maintains visual acuity gains through 4 years in advanced RP

Retina Society 2026: Medium-dose OCU410 gene therapy cuts geographic atrophy progression by up to 32% in phase 2 trial

Retina Society 2026: LUGANO secondary data show reduced treatment burden with vorolanib insert despite missed primary end point

Aurion Biotech completes enrollment in phase 3 ASTRA study of AURN001 for corneal edema secondary to corneal endothelial dysfunction

Retina Society 2026: SOL-1 shows intravitreal axitinib hydrogel superior to aflibercept in wet AMD